1. Urinmarker beim Blasenkarzinom
   Oliver W. Hakenberg, 2018 CrossRef
2. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review
   Ashish M. Kamat et al, 2018, European Urology CrossRef
3. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
   Francesco Soria et al, 2018, World J Urol CrossRef
4. Predicting Response to Intravesical Therapy in Non–muscle-invasive Bladder Cancer
   Mahmoud Alameddine et al, 2018, European Urology Focus CrossRef
5. How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?
   Seok Joong Yun et al, 2016, Investig Clin Urol CrossRef
6. Inflammatory cytokines in bladder cancer
   Pejman Shadpour et al, 2019, J Cell Physiol CrossRef
7. Urinary biomarkers in bladder cancer
   Abhishek Bhat et al, 2019, Current Opinion in Urology CrossRef
8. Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics
   Aleksander Ślusarczyk et al, 2019, Int Urol Nephrol CrossRef
9. Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette–Guérin
   Xiaoxuan Liu et al, 2014, Future Oncology CrossRef
10. Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond
    Yin Wu et al, 2015, Expert Review of Anticancer Therapy CrossRef
11. Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studies
    Alex Kiselyov et al, 2015, BBA Clinical CrossRef
12. Chronic inflammation in urothelial bladder cancer
    Gabriella Nesi et al, 2015, Virchows Arch CrossRef
13. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer
    Aurélie Mbeutcha et al, 2016, Urologic Clinics of North America CrossRef
14. Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer
    Selma Gogalic et al, 2017, Biomarkers CrossRef
15. Salvage Therapies for Non–muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms
    Óscar Rodríguez Faba et al, 2020, Urologic Clinics of North America CrossRef
16. Predictors of Response to Intravesical Therapy
    Roger Li et al, 2020, Urologic Clinics of North America CrossRef
17. Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guérin (BCG) and to oxidative damage
    Paulo F. Severino et al, 2017, Oncotarget CrossRef
18. Urinary Biomarkers: Current Status and Future Opportunities
    Ibardo A. Zambrano et al, 2021 CrossRef
19. Inflammation and Urothelial Bladder Cancer: What we Need to Known? (Review)
    null Tommaso Cai et al, 2015, J. Anal. Oncol. CrossRef
20. The Effect of Transurethral Resection and BCG Therapy on Cytokine Levels in Non-Muscle Invasive Bladder Cancer
    Oktay Üçer et al, 2022, jus CrossRef
21. Laboratory predictors to intravesical BCG therapy response in patients with non-muscle invasive bladder cancer
    S. Yu. Konyashkina et al, 2022, Vestn. Urol. CrossRef
22. Identifying novel biomarkers associated with bladder cancer treatment outcomes
    Peris R. Castaneda et al, 2023, Front. Oncol. CrossRef
23. Similar immune responses to alpha1‐oleate and Bacillus Calmette–Guérin treatment in patients with bladder cancer
    Shahram Ahmadi et al, 2024, Cancer Medicine CrossRef
24. The impact of purified protein derivative prior to intravesical bacillus Calmette-Guérin for the treatment of patients with non-muscle invasive bladder cancer
    Mohamed ZAWKY et al, 2024, Minerva Urol Nephrol CrossRef